


Clinical Trials Batch Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts



Patient & Document Source

Patient: Unknown Patient

Input Method: Clinical notes entered manually

Summary

Total Trials Assessed: 14

Matches: 1 | **No Match:** 13 | **Insufficient Info:** 0 | **Errors:** 0

#	NCT ID	Source	Trial Title	Result	Confidence
1	NCT03785249	—	A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849	NO MATCH	0.97
2	NCT04333706		A Dose Finding Phase 1 of Sarilumab Plus Capecitabine i	NO MATCH	0.99
3	NCT04913285		A Phase 1/1b Open-label, Multicenter Study to Investiga	NO MATCH	0.95
4	NCT05238922		A Phase 1, Open-Label, Multicenter Study of INCB123667	NO MATCH	0.95
5	NCT05538130		A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS	NO MATCH	0.98
6	NCT06108050		A Phase 1, First-in-human, Open-label, Multicenter Stud	MATCH	0.78
7	NCT06151574		Beamion LUNG 2: A Phase III, Open-label, Randomized, Ac	NO MATCH	0.95
8	NCT06246110		A Phase 2 Study of EIK1001 in Combination With Pembrol	NO MATCH	0.95

#	NCT ID	Source	Trial Title	Result	Confidence
9	NCT06252649		Phase 3 Multicenter, Randomized, Open-label, Active-con	NO MATCH	0.99
10	NCT06538038		Prospective Non-Interventional Study Comparing Standard	NO MATCH	0.90
11	NCT06581432		Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohor	NO MATCH	0.95
12	NCT06585488		A Phase 1a/1b Study to Investigate the Safety, Tolerabi	NO MATCH	0.95
13	NCT06634589		A Phase 1b/2, Open-Label, Master Protocol Study of BTK-	NO MATCH	0.99
14	NCT06946797		A Phase 2, Open-label, Randomized Trial to Evaluate Two	NO MATCH	0.97

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT03785249](#)

Result: **NO MATCH**

Confidence Score: 0.97

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type
- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy

- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times$ ULN (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: ≤ 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: NOT MATCH

Justification: The trial's disease_targets include Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Colonic Neoplasms, and Pancreatic Neoplasms. While the generic terms (Advanced Cancer, Metastatic Cancer, Neoplasms) could broadly encompass NSCLC, the critical issue is that the trial requires a KRAS G12C mutation. The patient has NSCLC with EGFR exon 19 deletion and KRAS Wild-type status (confirmed by clinician). The disease target match is secondary to the biomarker mismatch, but the trial does list generic cancer categories that could include NSCLC.

5. Eligibility Criteria Assessment

Summary: 6 met/clear | 1 unmet | 0 uncertain

Unmet Criteria

Criterion	Type	Status
KRAS G12C mutation - Patient's KRAS status is Wild-type (confirmed by clinician answer: 'Is your KRAS G12C Mutated? No'). This is a mandatory biomarker requirement for trial enrollment.	Inclusion	Unmet / Triggered

Met / Clear Criteria

Criterion	Type	Status
Histologically confirmed diagnosis of a solid tumor malignancy - Patient has histologically confirmed metastatic adenocarcinoma of the lung (NSCLC)	Inclusion	Met / Clear
Unresectable or metastatic disease - Patient has metastatic NSCLC with bone, lung, and liver metastases	Inclusion	Met / Clear

Criterion	Type	Status
Standard treatment is not available or patient declines - Patient has progressed on osimertinib (standard targeted therapy for EGFR-mutant NSCLC)	Inclusion	Met / Clear
Adequate organ function - Clinician confirmed: Bilirubin $\leq 1.5x$ ULN, AST $\leq 5x$ ULN, ALT $\leq 5x$ ULN, ANC $\geq 1500/\mu\text{L}$, Platelets $\geq 100,000/\mu\text{L}$, eGFR ≥ 60 mL/min, Hemoglobin ≥ 10 g/dL, Creatinine $\leq 1.5x$ ULN, WBC $\geq 3000/\mu\text{L}$, Alkaline Phosphatase $\leq 5x$ ULN, QTc ≤ 450 msec	Inclusion	Met / Clear
History of intestinal disease or major gastric surgery or inability to swallow oral medications - No significant comorbidities documented	Exclusion	Met / Clear
Other active cancer - Patient has a single primary diagnosis of NSCLC with no other active cancer mentioned	Exclusion	Met / Clear

6. Overall Rationale

The patient is a 70-year-old male with metastatic NSCLC (adenocarcinoma) with EGFR exon 19 deletion who has progressed on osimertinib. The critical inclusion criterion for this trial is the presence of a KRAS G12C mutation. The clinician has confirmed that the patient's KRAS status is Wild-type and specifically that KRAS G12C is NOT mutated. This is a mandatory biomarker requirement that the patient does not meet, resulting in a NO_MATCH determination regardless of other criteria being met.

***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

USC: Stephanie Kim (CISO) — stephanie.kim2@med.usc.edu

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT04333706](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.99

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: NOT MATCH

Justification: The trial targets metastatic triple negative breast cancer (TNBC) or hormone resistant, HER2-negative breast cancer. The patient has metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletion mutation. Lung cancer is a completely different cancer type from breast cancer and does not match any of the disease targets listed (Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell, Neoplasm Metastasis, Neoplasms). While 'Cancer' and 'Neoplasms' are generic terms, the trial specifically requires breast cancer diagnosis as confirmed by the inclusion criteria requiring TNBC or hormone-resistant HER2-negative breast cancer.

5. Eligibility Criteria Assessment

Summary: 17 met/clear | 3 unmet | 2 uncertain

Unmet Criteria

Criterion	Type	Status
[DIAGNOSIS] Patient does not have metastatic triple negative or hormone resistant, HER2-negative breast cancer. Patient has metastatic NSCLC (adenocarcinoma) with EGFR exon 19 deletion.	Inclusion	Unmet / Triggered
[BIOMARKER] Patient does not have a diagnosis of TNBC (ER/PR IHC positivity rate <10% and HER2-negative). Patient has NSCLC.	Inclusion	Unmet / Triggered
[DISEASE_STAGE] Patient does not have stage I, II, or III breast cancer with less than complete pCR. Patient has metastatic NSCLC.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[OTHER] Life expectancy of at least 6 months - not explicitly documented, though ECOG 0 suggests reasonable prognosis.	Inclusion	Uncertain
[PRIOR_TREATMENT] Phase I prior treatment requirements (cytotoxic chemotherapy timing, capecitabine restrictions) - patient has only received osimertinib (targeted therapy, not cytotoxic chemotherapy), and these criteria are not applicable given disease mismatch.	Inclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[AGE] Patient is 70 years old, which is ≥ 18 years of age.	Inclusion	Met / Clear
[PERFORMANCE_STATUS] ECOG Performance Status is 0, which is ≤ 2 .	Inclusion	Met / Clear
[ORGAN_FUNCTION] ANC ≥ 1500 /mcl - confirmed by clinician answer: ≥ 1500 / μ L.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Platelets $\geq 100,000$ /mcl - confirmed by clinician answer: $\geq 100,000$ / μ L.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Hemoglobin ≥ 9 - confirmed by clinician answer: ≥ 10 g/dL.	Inclusion	Met / Clear
[ORGAN_FUNCTION] ALT ≤ 5 x ULN - confirmed by clinician answer: ≤ 5 x ULN.	Inclusion	Met / Clear
[ORGAN_FUNCTION] AST ≤ 5 x ULN - confirmed by clinician answer: ≤ 5 x ULN.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Bilirubin ≤ 3 x ULN - confirmed by clinician answer: ≤ 1.5 x ULN.	Inclusion	Met / Clear
[ORGAN_FUNCTION] GFR ≥ 30 ml/min - confirmed by clinician answer: eGFR ≥ 60 mL/min.	Inclusion	Met / Clear
[COMORBIDITY] No significant comorbidities documented; no history of disease contraindicating protocol therapy.	Exclusion	Met / Clear
[INFECTION] Hepatitis B infection - patient is HIV negative and Hepatitis C negative; no Hepatitis B mentioned.	Exclusion	Met / Clear
[INFECTION] Known history of tuberculosis - not documented in patient history.	Exclusion	Met / Clear
[COMORBIDITY] History of diverticulitis - not documented.	Exclusion	Met / Clear
[MEDICATION] Use of live vaccines within 30 days - not documented.	Exclusion	Met / Clear
[COMORBIDITY] History of other malignancy with higher risk of recurrence/death - not documented.	Exclusion	Met / Clear
[OTHER] Prisoners or involuntarily incarcerated - no indication.	Exclusion	Met / Clear
[OTHER] Compulsorily detained for psychiatric or physical illness - no indication.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletion, which is fundamentally different from the trial's target disease of metastatic triple negative breast cancer (TNBC) or hormone-resistant HER2-negative breast cancer. The disease target does not match, and multiple key inclusion criteria related to breast cancer diagnosis, TNBC biomarker status, and breast cancer staging are unmet. Despite the patient meeting several organ function and performance status criteria, the fundamental disease mismatch makes this patient ineligible for this trial.

***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

CEDARS: Dr. Omid Hamid — ohamid@theangelesclinic.org

OPN: Heather Lyon — heatherl@opnhc.com

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT04913285](#)

Trial Source: ██████████

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative

- KRAS status: Wild-type
- Is your WBC \geq 3000/ μ L: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: \leq 5 x ULN (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: \leq 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic Non-Small Cell Lung Cancer (NSCLC), which directly matches 'Non-Small Cell Lung Cancer' and 'Carcinoma, Non-Small-Cell Lung' in the disease_targets list. The patient also has metastatic disease matching 'Neoplasm Metastasis' and 'Solid Tumor, Adult'.

5. Eligibility Criteria Assessment

Summary: 9 met/clear | 2 unmet | 2 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation - Patient's BRAF is Wild-type (confirmed by clinician) and NRAS is Wild-type (confirmed by clinician). The patient does not have a qualifying BRAF alteration or NRAS mutation. This is a critical inclusion criterion that is not met.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[IMAGING] Measurable or evaluable disease by RECIST v1.1 - Cannot be confirmed from available data, but this is secondary to the biomarker unmet criterion.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[IMAGING] Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1 - No imaging data provided to confirm measurable/evaluable disease per RECIST v1.1.	Inclusion	Uncertain
[PRIOR_TREATMENT] Known participants who have received local therapy with either surgery and/or radiation therapy - No information about prior surgery or radiation therapy provided.	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[DISEASE_STAGE] Metastatic or advanced stage solid tumor - Patient has metastatic NSCLC with bone, lung, and liver metastases.	Inclusion	Met / Clear
[PERFORMANCE_STATUS] ECOG performance status 0-1 - Patient has ECOG 0.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Adequate organ function - Clinician confirmed: Bilirubin $\leq 1.5x$ ULN, AST $\leq 5x$ ULN, ALT $\leq 5x$ ULN, ANC $\geq 1500/\mu L$, Platelets $\geq 100,000/\mu L$, eGFR ≥ 60 mL/min, Hemoglobin ≥ 10 g/dL, Creatinine $\leq 1.5x$ ULN, WBC $\geq 3000/\mu L$, Alkaline Phosphatase $\leq 5x$ ULN, QTc ≤ 450 msec.	Inclusion	Met / Clear
[OTHER] Able to swallow, retain, and absorb oral medications - No GI issues documented; patient tolerated osimertinib (oral). Procedural - completable at enrollment.	Inclusion	Met / Clear
[PRIOR_TREATMENT] In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy - Patient has only received osimertinib (EGFR inhibitor), not BRAF/MEK/MAPK inhibitors.	Exclusion	Met / Clear
[COMORBIDITY] GI tract disease causing inability to take oral medication, malabsorption syndrome, requirement for IV alimentation, or uncontrolled inflammatory GI disease - No GI comorbidities documented.	Exclusion	Met / Clear
[INFECTION] Active, uncontrolled bacterial, fungal, or viral infection - No active infections documented; HIV negative, Hepatitis C negative.	Exclusion	Met / Clear
[INFECTION] Positive SARS-CoV2 test or suspected infection - No COVID-19 mentioned.	Exclusion	Met / Clear
[COMORBIDITY] Any other active treated malignancy within 3 years prior to enrollment - Only NSCLC documented.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC which matches the disease targets. However, the critical biomarker inclusion criterion requires a known BRAF Class I, II, or III alteration OR melanoma with NRAS mutation. The patient's BRAF is confirmed Wild-type and NRAS is confirmed Wild-type, meaning neither qualifying biomarker alteration is present. This unmet inclusion criterion disqualifies the patient from this trial, which is designed for patients with BRAF/NRAS alterations. The result is NO_MATCH.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT05238922](#)

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type
- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy

- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times$ ULN (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: ≤ 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: NOT MATCH

Justification: The patient has Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletion. The disease_targets listed are: Solid Tumors, Breast Neoplasms, Carcinoma Ovarian Epithelial, and Digestive System Neoplasms. While the trial includes a 'Disease Group 6: Other tumor indications excluding bone cancers' in Part 1A, the disease_targets field does not include lung cancer as a specific target. However, 'Solid Tumors' is listed as a disease target, and NSCLC is a solid tumor. The Part 1A dose escalation includes 'advanced or metastatic solid tumors' broadly. Despite this, the specific disease groups in Part 2 focus on breast cancer and ovarian cancer, and the trial's primary disease targets do not specifically include lung cancer. That said, 'Solid Tumors' as a disease target could encompass NSCLC. Evaluating further based on inclusion/exclusion criteria is warranted, but the disease match is uncertain given the broad 'Solid Tumors' listing.

5. Eligibility Criteria Assessment

Summary: 14 met/clear | 10 unmet | 9 uncertain

Unmet Criteria

Criterion	Type	Status
[DIAGNOSIS] Disease Group 1: Ovarian/Fallopian/Primary Peritoneal Cancer - Patient does not have this cancer type.	Inclusion	Unmet / Triggered
[DIAGNOSIS] Disease Group 2: Endometrial/Uterine Cancer - Patient does not have this cancer type.	Inclusion	Unmet / Triggered
[DIAGNOSIS] Disease Group 3: Gastric, GEJ, and esophageal carcinomas - Patient does not have this cancer type.	Inclusion	Unmet / Triggered
[DIAGNOSIS] Disease Group 4: TNBC - Patient does not have TNBC.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[BIOMARKER] Disease Group 5: HR+/HER2- breast cancer - Patient does not have breast cancer.	Inclusion	Unmet / Triggered
[BIOMARKER] TGA, TGC, TGE, TGF, TGG: HR+/HER2- breast cancer - Patient does not have HR+/HER2- breast cancer.	Inclusion	Unmet / Triggered
[BIOMARKER] TGB and TGD: HR+/HER2- breast cancer - Patient does not have HR+/HER2- breast cancer.	Inclusion	Unmet / Triggered
[BIOMARKER] TGH and TGJ: HR+/HER2- breast cancer - Patient does not have HR+/HER2- breast cancer.	Inclusion	Unmet / Triggered
[BIOMARKER] TGI and TGK: HR+/HER2- breast cancer - Patient does not have HR+/HER2- breast cancer.	Inclusion	Unmet / Triggered
[DIAGNOSIS] TGL, TGM and TGN: Advanced or metastatic epithelial ovarian/fallopian/primary peritoneal carcinoma - Patient does not have ovarian cancer.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[OTHER] Life expectancy greater than 12 weeks - Not explicitly documented in patient notes.	Inclusion	Uncertain
[IMAGING] Measurable lesions by CT or MRI based on RECIST v1.1 criteria - Not explicitly confirmed in patient notes, though metastatic disease is present.	Inclusion	Uncertain
[CNS] Untreated brain or central nervous system (CNS) metastases - Bone, lung, and liver metastases documented, but CNS metastases status not explicitly addressed.	Exclusion	Uncertain
[TIMING] Any change in endocrine therapy within 5 half-lives or 28 days before first dose - Not applicable for this patient (no endocrine therapy), but timing of last osimertinib dose not documented.	Exclusion	Uncertain
[TIMING] Any major surgery within 28 days before the first dose of study drug - Not documented.	Exclusion	Uncertain
[TIMING] Any prior radiation therapy within 28 days before the first dose of study drug - Not documented.	Exclusion	Uncertain
[TIMING] Undergoing treatment with another investigational medication within 5 half-lives or 28 days - Not documented.	Exclusion	Uncertain
[ORGAN_FUNCTION] Specific laboratory values - Clinician confirmed values appear within acceptable ranges.	Exclusion	Uncertain
[ORGAN_FUNCTION] History or presence of an ECG abnormality - QTc \leq 450 msec confirmed by clinician, but full ECG history not documented.	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[AGE] Adults aged 18 years or older - Patient is 70 years old, meets this criterion.	Inclusion	Met / Clear
[PERFORMANCE_STATUS] ECOG performance status score of 0 or 1 - Patient has ECOG 0.	Inclusion	Met / Clear
[TREATMENT_RESPONSE] Disease progression on prior standard treatment - Patient progressed on osimertinib (standard targeted therapy for EGFR-mutated NSCLC).	Inclusion	Met / Clear

Criterion	Type	Status
[OTHER] Availability of a baseline archival tumor specimen or willingness to undergo a pretreatment and on-treatment tumor biopsy - Procedural - completable at enrollment.	Inclusion	Met / Clear
[DIAGNOSIS] Participants in Part 1A (dose escalation): Histologically or cytologically confirmed advanced or metastatic solid tumors - Patient has metastatic NSCLC adenocarcinoma, which is a solid tumor.	Inclusion	Met / Clear
[IMAGING] Measurable lesions by CT or MRI based on RECIST v1.1 criteria - Not explicitly confirmed, but patient has metastatic disease at multiple sites; procedural assessment at enrollment.	Inclusion	Met / Clear
[INFECTION] Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment - No significant comorbidities documented.	Exclusion	Met / Clear
[INFECTION] Active HBV or HCV infection that requires treatment - Hepatitis C negative.	Exclusion	Met / Clear
[INFECTION] Known history of HIV - HIV negative.	Exclusion	Met / Clear
[PRIOR_TREATMENT] Prior treatment with any CDK2 inhibitor - No CDK2 inhibitor treatment documented.	Exclusion	Met / Clear
[ALLERGY] Known hypersensitivity or severe reaction to any component of study treatment - No allergies documented.	Exclusion	Met / Clear
[COMORBIDITY] Known additional malignancy that is progressing or requires active treatment - No additional malignancy documented.	Exclusion	Met / Clear
[COMORBIDITY] History of clinically significant or uncontrolled cardiac disease - No significant comorbidities documented.	Exclusion	Met / Clear
[TREATMENT_RESPONSE] Has not recovered to \leq Grade 1 from toxic effects of prior therapy - Patient had no toxicity from osimertinib.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC (adenocarcinoma) with EGFR exon 19 deletion who progressed on osimertinib. While 'Solid Tumors' is listed as a disease target and NSCLC is technically a solid tumor, the trial's specific disease groups in Part 2 focus exclusively on breast cancer (HR+/HER2-) and ovarian/fallopian/peritoneal carcinoma. The patient does not match any of the specific disease groups (Groups 1-6 in Part 1B, or any Part 2 treatment groups). The patient could potentially qualify for Part 1A dose escalation as an advanced solid tumor, and Disease Group 6 ('Other tumor indications excluding bone cancers') could include NSCLC. However, the patient has bone metastases, which may exclude them from Disease Group 6 ('excluding bone cancers'). Furthermore, the trial appears primarily focused on CDK2 inhibition in hormone receptor-positive breast cancer and gynecologic cancers, making NSCLC a poor fit. The overall assessment is NO_MATCH primarily because the patient's cancer type (NSCLC) does not fit the specific disease groups, and the bone metastases may exclude from Disease Group 6.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

USC: Stephanie Kim (CISO) — stephanie.kim2@med.usc.edu

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT05538130](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.98

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR T790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR EXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic Non-Small Cell Lung Cancer (NSCLC), which is explicitly listed in the disease_targets as 'Non-Small Cell Lung Cancer', 'NSCLC (Non-small Cell Lung Cancer)', and 'Carcinoma, Non-Small-Cell Lung'.

5. Eligibility Criteria Assessment

Summary: 10 met/clear | 1 unmet | 0 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] Evidence of a BRAF V600 mutation - Patient's BRAF status is Wild-type; BRAFV600E is Wild-type per clinician confirmation. The patient does NOT have a BRAF V600 mutation, which is a required inclusion criterion.	Inclusion	Unmet / Triggered

Met / Clear Criteria

Criterion	Type	Status
[DIAGNOSIS] Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer) - Patient has metastatic NSCLC, not colorectal cancer	Inclusion	Met / Clear
[IMAGING] Measurable disease by RECIST version 1.1 - Patient has metastatic disease with multiple sites (bone, lung, liver); measurable disease assumed given active metastatic disease	Inclusion	Met / Clear
[ORGAN_FUNCTION] Adequate organ function per protocol - Clinician confirmed: Bilirubin $\leq 1.5x$ ULN, AST $\leq 5x$ ULN, ALT $\leq 5x$ ULN, ANC $\geq 1500/\mu\text{L}$, Platelets $\geq 100000/\mu\text{L}$, eGFR ≥ 60 mL/min, Hemoglobin ≥ 10 g/dL, Creatinine $\leq 1.5x$ ULN, WBC $\geq 3000/\mu\text{L}$, Alkaline Phosphatase $\leq 5x$ ULN, QTc ≤ 450 msec	Inclusion	Met / Clear
[PRIOR_TREATMENT] Prior therapy per tumor cohort - Patient has received and progressed on osimertinib (prior EGFR-targeted therapy)	Inclusion	Met / Clear
[DIAGNOSIS] Other active malignancy within 3 years - No other malignancy documented	Exclusion	Met / Clear
[CNS] Presence of leptomeningeal disease - No leptomeningeal disease documented	Exclusion	Met / Clear
[COMORBIDITY] History or current evidence of retinal vein occlusion (RVO) or history of retinal degenerative disease - No such history documented	Exclusion	Met / Clear
[COMORBIDITY] Concurrent neuromuscular disorder associated with elevated creatine kinase (CK) - No such disorder documented	Exclusion	Met / Clear
[COMORBIDITY] Active gastrointestinal disease as defined per protocol - No significant comorbidities documented	Exclusion	Met / Clear
[COMORBIDITY] History of interstitial lung disease as defined per protocol - No such history documented	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC which matches the disease targets. However, the critical inclusion criterion requiring evidence of a BRAF V600 mutation is NOT met. The patient's BRAF status is Wild-type (confirmed by both biomarker data and clinician confirmation that BRAF V600E is Wild-type). This trial is specifically designed for patients with BRAF V600 mutations, and the patient lacks this required biomarker. Therefore, the patient is NOT eligible for this trial.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06108050](#)

Trial Source: ██████████

Result: **MATCH**

Confidence Score: 0.78

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative

- KRAS status: Wild-type
- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: ≤ 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic NSCLC (adenocarcinoma with bone, lung, and liver metastases), which qualifies as an 'Advanced Solid Tumor' or 'Metastatic Solid Tumor' as listed in the disease_targets. NSCLC is also explicitly mentioned in the inclusion criteria as an eligible tumor type for CPI therapy.

5. Eligibility Criteria Assessment

Summary: 17 met/clear | 0 unmet | 6 uncertain

Uncertain Criteria

Criterion	Type	Status
[PRIOR_TREATMENT] NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion - The notes document only osimertinib as prior therapy. It is not confirmed whether the patient received platinum-based chemotherapy prior to study entry.	Inclusion	Uncertain

Criterion	Type	Status
[TREATMENT_RESPONSE] Parts A2 and B: previously-treated (≥ 1 line of prior anticancer therapy) participants with NSCLC who have progressed on/after prior CPI therapy - The patient progressed on osimertinib (targeted therapy), not on CPI (checkpoint inhibitor) therapy. It is unclear whether the patient has received and progressed on prior CPI therapy, which is required for Parts A2 and B.	Inclusion	Uncertain
[IMAGING] Measurable disease per RECIST version 1.1 criteria - No imaging data provided to confirm measurable disease.	Inclusion	Uncertain
[TIMING] Received any anticancer therapy within 5 half-lives or 4 weeks prior to first dose - Osimertinib was discontinued but no end date is provided; timing relative to study entry is unknown.	Exclusion	Uncertain
[TIMING] Received prior radiotherapy within 2 weeks of first dose or history of radiation pneumonitis - No radiotherapy history documented, but cannot confirm absence.	Exclusion	Uncertain
[TIMING] Major surgery within 2 weeks prior to first dose - No surgery history documented, but cannot confirm absence.	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[AGE] Adult ≥ 18 years of age - Patient is 70 years old.	Inclusion	Met / Clear
[DIAGNOSIS] Histological or cytological diagnosis of advanced or metastatic solid tumor - Patient has metastatic NSCLC adenocarcinoma.	Inclusion	Met / Clear
[PRIOR_TREATMENT] Previously treated participants with solid tumors amenable to CPI therapy (NSCLC) for whom there is no SoC available - Patient has progressed on osimertinib (standard targeted therapy for EGFR-mutant NSCLC), making CPI therapy a potential option.	Inclusion	Met / Clear
[PRIOR_TREATMENT] NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion - Patient progressed on osimertinib; platinum-based therapy eligibility is standard for post-osimertinib NSCLC. (Note: platinum receipt not explicitly documented but patient is post-targeted therapy progression; however this is uncertain - see uncertain_criteria)	Inclusion	Met / Clear
[PERFORMANCE_STATUS] ECOG score of 0 to 1 - Patient has ECOG 0.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Adequate organ and bone marrow function - Clinician confirmed: Bilirubin $\leq 1.5x$ ULN, AST $\leq 5x$ ULN, ALT $\leq 5x$ ULN, ANC $\geq 1500/\mu\text{L}$, Platelets $\geq 100,000/\mu\text{L}$, eGFR ≥ 60 mL/min, Hemoglobin ≥ 10 g/dL, Creatinine $\leq 1.5x$ ULN, WBC $\geq 3000/\mu\text{L}$, Alkaline Phosphatase $\leq 5x$ ULN, QTc ≤ 450 msec.	Inclusion	Met / Clear
[PRIOR_TREATMENT] Unresolved toxicities from previous therapy $>$ Grade 1 - Patient had no toxicity from osimertinib per medical history.	Inclusion	Met / Clear
Informed consent / willingness to comply with study procedures - Procedural - completable at enrollment.	Inclusion	Met / Clear
[ALLERGY] Hypersensitivity to mAb, IFN α , or study intervention components - No allergies documented.	Exclusion	Met / Clear
[CNS] Primary CNS tumor or symptomatic CNS metastases - No CNS metastases documented.	Exclusion	Met / Clear
[COMORBIDITY] Second primary malignancy treated within the previous 2 years - No second malignancy documented.	Exclusion	Met / Clear
[AUTOIMMUNE] Active autoimmune disease requiring systemic steroids or immunosuppressive agents - No autoimmune disease documented.	Exclusion	Met / Clear

Criterion	Type	Status
[COMORBIDITY] Active or history of pneumonitis/interstitial lung disease requiring steroids - No such history documented.	Exclusion	Met / Clear
[COMORBIDITY] Any history of suicidal behavior or suicidal ideation - No such history documented.	Exclusion	Met / Clear
[COMORBIDITY] Clinically significant ischemic/hemorrhagic cerebrovascular accident/stroke and/or clinically significant active cardiovascular disease - No significant comorbidities documented.	Exclusion	Met / Clear
[PRIOR_TREATMENT] Had a stem cell/solid organ transplant - No transplant history documented.	Exclusion	Met / Clear
[PRIOR_TREATMENT] Receipt of prior IFN α therapy - No IFN α therapy documented.	Exclusion	Met / Clear

6. Overall Rationale

The patient is a 70-year-old male with metastatic NSCLC (EGFR exon 19 deletion, adenocarcinoma) who progressed on osimertinib, with ECOG 0 and adequate organ function confirmed by clinician. The disease target matches (metastatic solid tumor/NSCLC). Key uncertainties include: (1) whether the patient received prior platinum-based chemotherapy as required for NSCLC inclusion; (2) whether the patient has progressed on prior CPI therapy (required for Parts A2 and B); and (3) measurable disease per RECIST. The patient has not received CPI therapy per available records, which is a significant concern for Parts A2 and B eligibility, though Part A1 (dose escalation) may not require prior CPI progression. Overall, the patient appears potentially eligible for Part A1 of the trial, but eligibility for Parts A2/B is uncertain due to lack of documented prior CPI therapy progression and platinum-based chemotherapy. Given the overall framework and that Part A1 eligibility appears met, a MATCH is assigned with moderate confidence.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06151574](#)

Trial Source: ██████████

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type

- ALK status: Negative
- KRAS status: Wild-type
- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: ≤ 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic non-small cell lung cancer (adenocarcinoma histology), which matches the disease targets 'Lung Cancer, Non-squamous, Non-small Cell' and 'Lung Neoplasms'. Adenocarcinoma is a non-squamous NSCLC.

5. Eligibility Criteria Assessment

Summary: 12 met/clear | 2 unmet | 4 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] Documented HER2 mutation in the Tyrosine kinase domain (TKD): The patient's HER2 status is confirmed NEGATIVE by both biomarker data and clinician-confirmed answer ('Negative'). This is a required inclusion criterion and is not met.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[PRIOR_TREATMENT] Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease: The patient has received and discontinued osimertinib for metastatic disease, meaning they have received prior systemic treatment. This criterion requires treatment-naive patients for metastatic disease.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[BIOMARKER] Archival tumor tissue sample availability for central laboratory submission.	Inclusion	Uncertain
[OTHER] Eligibility to receive platinum-based doublet chemotherapy (cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab per SmPC - not fully confirmed but eGFR >60 and normal organ function suggest likely eligible.	Inclusion	Uncertain
[ORGAN_FUNCTION] Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG - no ECG data available beyond QTc ≤450 msec.	Inclusion	Uncertain
[OTHER] Any history of or concomitant condition that would compromise the patient's ability to comply with the trial - insufficient detail to fully exclude.	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[AGE] Patient is 70 years old, which is ≥18 years of age.	Inclusion	Met / Clear
[DIAGNOSIS] Histologically confirmed advanced/metastatic non-squamous NSCLC (adenocarcinoma).	Inclusion	Met / Clear
[IMAGING] Patient has metastatic disease with multiple sites (bone, lung, liver), likely has measurable lesions per RECIST 1.1 - to be confirmed at enrollment.	Inclusion	Met / Clear
[DIAGNOSIS] No mention of other malignancies within the last 5 years.	Inclusion	Met / Clear
[OTHER] Ability to provide written informed consent - Procedural - completable at enrollment.	Inclusion	Met / Clear
[OTHER] Willingness to comply with study procedures - Procedural - completable at enrollment.	Inclusion	Met / Clear
[COMORBIDITY] No significant comorbidities documented; no lung-specific intercurrent clinically significant severe illness.	Exclusion	Met / Clear
[COMORBIDITY] No history of cardiovascular abnormalities such as uncontrolled hypertension, CHF NYHA ≥III/IV, unstable angina, or poorly controlled arrhythmia documented.	Exclusion	Met / Clear
[TIMING] No myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization documented.	Exclusion	Met / Clear
[BIOMARKER] No targetable alterations with approved therapy other than EGFR (ALK negative, ROS1 negative, BRAF V600E wild-type, KRAS G12C negative, RET negative, NTRK negative, MET exon 14 skipping wild-type, tumor activating fusions negative).	Exclusion	Met / Clear
[MEDICATION] No restricted medications mentioned.	Exclusion	Met / Clear
[TIMING] No major surgery within 4 weeks prior to randomization documented.	Exclusion	Met / Clear

6. Overall Rationale

The patient does not meet two critical inclusion criteria: (1) The trial requires a documented HER2 mutation in the tyrosine kinase domain, but the patient's HER2 status is confirmed NEGATIVE by both biomarker data and clinician-confirmed answer. (2) The trial requires patients who have NOT received any prior systemic treatment for metastatic disease, but this patient has already received and discontinued osimertinib for metastatic EGFR-mutant NSCLC. These two unmet inclusion criteria result in a NO_MATCH determination. Additionally, the patient has an EGFR exon 19 deletion with sensitizing EGFR mutation, which represents a targetable alteration with approved available therapy - this may also be an issue per the inclusion criterion regarding tumors with targetable alterations with approved available therapy (though this criterion appears to be listed under inclusion as an exclusionary note).


***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts



1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06246110](#)

Trial Source: [REDACTED]

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative

- KRAS status: Wild-type
- Is your WBC \geq 3000/ μ L: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: \leq 5 x ULN (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: \leq 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic Non-Small Cell Lung Cancer (NSCLC) with adenocarcinoma histology, which directly matches the disease targets 'NSCLC' and 'Neoplasm Metastasis' listed in the trial.

5. Eligibility Criteria Assessment

Summary: 10 met/clear | 3 unmet | 0 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations/fusions that are approved for first line therapy). The patient has an EGFR exon 19 deletion mutation, which is an activating mutation approved for first-line targeted therapy. The clinician confirmed 'Egfrsensitizing' is mutated (not wild-type). Therefore, mutation-directed therapy IS indicated for this patient, and this criterion is NOT met.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[PRIOR_TREATMENT] have not received prior systemic treatment for advanced/metastatic NSCLC. The patient has received and discontinued osimertinib for metastatic NSCLC, and has progressed on it. This criterion is not met.	Inclusion	Unmet / Triggered
[PRIOR_TREATMENT] prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease. The patient received osimertinib for metastatic NSCLC and progressed on it, triggering this exclusion criterion.	Exclusion	Unmet / Triggered

Met / Clear Criteria

Criterion	Type	Status
[AGE] be \geq 18 years of age on the day of signing of informed consent. Patient is 70 years old.	Inclusion	Met / Clear
[DISEASE_STAGE] confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care. Patient has metastatic (Stage 4) NSCLC with adenocarcinoma (non-squamous) histology.	Inclusion	Met / Clear
[IMAGING] have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1. Patient has metastatic disease in bone, lung, and liver - measurable disease is implied.	Inclusion	Met / Clear
[PERFORMANCE_STATUS] have an ECOG Performance Status of 0 to 1. Patient has ECOG 0.	Inclusion	Met / Clear
[ORGAN_FUNCTION] have adequate organ function. Clinician confirmed: Bilirubin \leq 1.5x ULN, AST \leq 5x ULN, ALT \leq 5x ULN, ANC \geq 1500/ μ L, Platelets \geq 100000/ μ L, eGFR \geq 60 mL/min, Hemoglobin \geq 10 g/dL, Creatinine \leq 1.5x ULN, WBC \geq 3000/ μ L, Alkaline Phosphatase \leq 5x ULN, QTc \leq 450 msec.	Inclusion	Met / Clear
[DISEASE_STAGE] does not have predominantly squamous cell or non-squamous cell histology NSCLC. Patient has adenocarcinoma (non-squamous), which is eligible histology. No small cell elements documented.	Exclusion	Met / Clear
[TIMING] is currently participating in or has participated in a study of an investigational agent within 4 weeks or 5 half-lives. No investigational agent use documented.	Exclusion	Met / Clear
[TIMING] has completed palliative radiotherapy within 7 days of the first dose. No recent radiotherapy documented.	Exclusion	Met / Clear
[COMORBIDITY] has a known history of prior malignancy. No prior malignancy documented.	Exclusion	Met / Clear
[INFECTION] has an active infection requiring therapy. No active infection documented.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC (adenocarcinoma) matching the disease targets. However, the patient is NOT eligible for this trial for two key reasons: (1) The patient has an EGFR exon 19 deletion mutation, which is an activating mutation with approved first-line targeted therapy, meaning mutation-directed therapy IS indicated – this fails the biomarker inclusion criterion requiring absence of such mutations. (2) The patient has already received prior systemic therapy for metastatic NSCLC (osimertinib) and progressed on it, which both fails the inclusion criterion requiring no prior systemic treatment and triggers the exclusion criterion for prior systemic therapy for metastatic disease. This trial appears designed for treatment-naïve Stage 4 NSCLC patients without actionable mutations, and this patient does not qualify.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06252649](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.99

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: NOT MATCH

Justification: The trial targets Metastatic Colorectal Cancer / Colorectal Neoplasms. The patient has metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletion. Lung cancer is not colorectal cancer and does not match any of the listed disease targets.

5. Eligibility Criteria Assessment

Summary: 4 met/clear | 3 unmet | 3 uncertain

Unmet Criteria

Criterion	Type	Status
[DIAGNOSIS] Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation - Patient has metastatic NSCLC (lung adenocarcinoma), not colorectal adenocarcinoma. Additionally, KRAS status is Wild-type (not G12C mutated) per clinician confirmation.	Inclusion	Unmet / Triggered
[BIOMARKER] Central laboratory detection of KRAS p.G12C mutation - KRAS is Wild-type; no KRAS G12C mutation present.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[IMAGING] Measurable metastatic disease per RECIST v1.1 criteria - Cannot confirm measurable disease per RECIST v1.1 from available data, but primary issue is disease type mismatch.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[IMAGING] Measurable metastatic disease per RECIST v1.1 criteria - No imaging data explicitly confirming RECIST v1.1 measurable disease documented.	Inclusion	Uncertain
[CNS] Active, untreated brain metastases - No brain metastasis data available.	Exclusion	Uncertain
[CNS] Leptomeningeal disease - No information available.	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[PERFORMANCE_STATUS] ECOG Performance Status \leq 1 - Patient has ECOG 0.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Adequate organ function - Clinician confirmed normal labs including creatinine \leq 1.5x ULN, bilirubin \leq 1.5x ULN, AST/ALT \leq 5x ULN, ANC \geq 1500/ μ L, platelets \geq 100,000/ μ L, hemoglobin \geq 10 g/dL, WBC \geq 3000/ μ L.	Inclusion	Met / Clear
[PRIOR_TREATMENT] Previous treatment with a KRAS p.G12C inhibitor - Patient has not received any KRAS G12C inhibitor; prior treatment was osimertinib (EGFR inhibitor).	Exclusion	Met / Clear
[COMORBIDITY] History of interstitial pneumonitis or pulmonary fibrosis - No such history documented; no significant comorbidities noted.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR exon 19 deletion, not metastatic colorectal adenocarcinoma. The trial specifically targets metastatic colorectal cancer with KRAS p.G12C mutation. The patient's KRAS status is confirmed Wild-type (no G12C mutation), and the primary cancer type does not match the trial's disease targets. The patient is therefore not eligible for this trial.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06538038](#)

Trial Source: ██████████

Result: **NO MATCH**

Confidence Score: 0.90

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR T790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: ≤ 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR EXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has a confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC), specifically metastatic adenocarcinoma of the lung with EGFR exon 19 deletion mutation. This directly matches the disease targets 'Non Small Cell Lung Cancer', 'Epidermal Growth Factor Receptor Gene Mutation', 'Stage IV Lung Cancer', and 'Carcinoma, Non-Small-Cell Lung'.

5. Eligibility Criteria Assessment

Summary: 5 met/clear | 2 unmet | 1 uncertain

Unmet Criteria

Criterion	Type	Status
[PRIOR_TREATMENT] Prior treatment with osimertinib administered as primary treatment for NSCLC is allowed \leq 30 days of study registration. The patient has already received and discontinued osimertinib, and has progressed on osimertinib (EGFRT790M status: 'Progressed after standard targeted therapy'). The criterion allows prior osimertinib only if administered \leq 30 days before study registration as primary treatment - but the patient has already completed/discontinued osimertinib treatment and progressed, suggesting this was not a recent start within 30 days. Furthermore, the trial appears to be designed for first-line treatment with osimertinib, and the patient has already progressed on osimertinib, making them ineligible for this first-line treatment trial.	Inclusion	Unmet / Triggered
[OTHER] The trial specifies that osimertinib or osimertinib + chemotherapy/immunotherapy given as first-line treatment cannot be given as part of a clinical trial - the patient has already received and progressed on osimertinib, suggesting they are beyond the first-line setting this trial targets.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[OTHER] Patient must not be participating in EA5182 or any other cancer treatment trial - no information provided about current trial participation.	Inclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[DIAGNOSIS] Patient has a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC) - adenocarcinoma histology confirmed.	Inclusion	Met / Clear
[DISEASE_STAGE] Patient has advanced/metastatic disease (Stage IV) with metastases to bone, lung, and liver, meeting the IIIB/IIIC/IV requirement.	Inclusion	Met / Clear
[BIOMARKER] Patient tumor has a somatic activating sensitizing EGFR mutation (Exon 19 deletion), which is explicitly listed as an eligible mutation. EGFR exon 20 insertion is confirmed absent.	Inclusion	Met / Clear
[PRIOR_TREATMENT] Patients that have received prior radiation therapy in any setting for this disease are eligible - not applicable but not disqualifying.	Inclusion	Met / Clear
[AGE] Patient is 70 years old, meeting the age \geq 18 years requirement.	Inclusion	Met / Clear

6. Overall Rationale

The patient has confirmed NSCLC with EGFR exon 19 deletion mutation and Stage IV disease, matching the disease targets. However, the patient has already received osimertinib as primary treatment and has progressed on it (EGFRT790M status indicates progression after standard targeted therapy). The trial's inclusion criterion allows prior osimertinib only if administered \leq 30 days of study registration, and the overall trial design is for first-line treatment with osimertinib. A patient who has already completed osimertinib treatment and progressed does not fit the intent of this first-line treatment trial. The patient is therefore NOT eligible for this trial.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care

decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06581432](#)

Trial Source: ██████████

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative

- KRAS status: Wild-type
- Is your WBC \geq 3000/ μ L: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR T790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: \leq 5 x ULN (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: \leq 450 msec (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR EXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The trial targets 'Solid Tumours' broadly. The patient has metastatic Non-Small Cell Lung Cancer (adenocarcinoma), which is a solid tumour. This matches the disease target.

5. Eligibility Criteria Assessment

Summary: 8 met/clear | 1 unmet | 0 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] The trial requires documented HER2 overexpression/amplification OR known activating HER2 mutations. The patient's HER2 status is confirmed Negative by both biomarker data and clinician-confirmed answer. The patient has EGFR exon 19 deletion mutation, not a HER2 alteration. Additionally, the inclusion criterion for HER2 mutant NSCLC specifically excludes cases with co-existing HER2 overexpression/amplification, and this patient has neither HER2 mutation nor overexpression. The patient does not meet the HER2 biomarker requirement.	Inclusion	Unmet / Triggered

Met / Clear Criteria

Criterion	Type	Status
[AGE] Patient is 70 years old, which is ≥ 18 years.	Inclusion	Met / Clear
[DIAGNOSIS] Patient has histologically confirmed metastatic solid tumour (metastatic NSCLC adenocarcinoma).	Inclusion	Met / Clear
[PRIOR_TREATMENT] Patient has had at least one prior line of therapy for metastatic disease (osimertinib, discontinued).	Inclusion	Met / Clear
[TREATMENT_RESPONSE] Patient progressed on osimertinib; in the investigator's opinion, further standard of care may not provide clinically meaningful benefit.	Inclusion	Met / Clear
[COMORBIDITY] No significant comorbidities documented; no previous or concomitant malignancies within the previous 3 years mentioned.	Inclusion	Met / Clear
[MEDICATION] No restricted medications mentioned.	Inclusion	Met / Clear
[PRIOR_TREATMENT] No major surgery mentioned; patient appears to have recovered from any prior procedures.	Inclusion	Met / Clear
No exclusion criteria were explicitly listed in the trial record.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC (adenocarcinoma), which qualifies as a solid tumour matching the disease target. However, the trial requires patients to have either HER2 overexpression/amplification or known activating HER2 mutations. The patient's HER2 status is confirmed Negative by both the biomarker data and the clinician-confirmed answer. The patient's driver mutation is EGFR exon 19 deletion, not HER2. Therefore, the critical HER2 biomarker inclusion criterion is not met, resulting in a NO_MATCH determination.

***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06585488](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.95

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFRT790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFREXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has metastatic non-squamous (adenocarcinoma) non-small cell lung cancer, which directly matches 'Advanced Non-squamous Non-small-cell Lung Cancer' in the disease_targets list.

5. Eligibility Criteria Assessment

Summary: 11 met/clear | 1 unmet | 1 uncertain

Unmet Criteria

Criterion	Type	Status
[BIOMARKER] Participants must have evidence of a KRAS mutation or wild-type amplification (copy number ≥ 8) - Patient's KRAS is Wild-type (confirmed by clinician) with no evidence of KRAS amplification (copy number ≥ 8) documented. The patient does not have a KRAS mutation, and there is no evidence of KRAS wild-type amplification ≥ 8 copies.	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[INFECTION] Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA \geq 500 IU/mL - HBV status not explicitly documented (though no mention of hepatitis B).	Exclusion	Uncertain

Met / Clear Criteria

Criterion	Type	Status
[PERFORMANCE_STATUS] ECOG Performance Status \leq 1 - Patient has ECOG 0.	Inclusion	Met / Clear
[OTHER] Able to provide an archived tumor tissue sample or fresh biopsy sample - Procedural - completable at enrollment.	Inclusion	Met / Clear
[IMAGING] \geq 1 measurable lesion per RECIST v1.1 - Patient has metastatic disease in bone, lung, and liver, suggesting measurable lesions are likely present.	Inclusion	Met / Clear
[ORGAN_FUNCTION] Adequate organ function - Clinician confirmed: Bilirubin \leq 1.5x ULN, AST \leq 5x ULN, ALT \leq 5x ULN, ANC \geq 1500/ μ L, Platelets \geq 100,000/ μ L, eGFR \geq 60 mL/min, Hemoglobin \geq 10 g/dL, Creatinine \leq 1.5x ULN, WBC \geq 3000/ μ L, Alkaline Phosphatase \leq 5x ULN, QTc \leq 450 msec.	Inclusion	Met / Clear
[BIOMARKER] Participants with tumors harboring KRAS G12R mutation - Clinician confirmed KRASG12R is Wild-type (not mutated).	Exclusion	Met / Clear
[PRIOR_TREATMENT] Prior therapy with anti-RAS treatment - Patient's only prior therapy was osimertinib (EGFR inhibitor), not an anti-RAS/KRAS treatment.	Exclusion	Met / Clear
[CNS] Active leptomeningeal disease or uncontrolled, untreated brain metastasis - No CNS metastases documented.	Exclusion	Met / Clear
[DIAGNOSIS] Any malignancy \leq 2 years before first dose except the specific cancer under investigation - No other malignancy documented.	Exclusion	Met / Clear
[INFECTION] Untreated chronic hepatitis B or HBV DNA \geq 500 IU/mL - Not documented; no hepatitis B mentioned.	Exclusion	Met / Clear
[INFECTION] Active hepatitis C - Clinician confirmed Hepatitis C negative.	Exclusion	Met / Clear
[INFECTION] Clinically significant infections requiring systemic antibacterial, antifungal, or antiviral therapy \leq 14 days before first dose - No significant infections documented.	Exclusion	Met / Clear

6. Overall Rationale

The patient has advanced non-squamous NSCLC (adenocarcinoma) which matches the disease target. However, the critical biomarker inclusion criterion requires evidence of a KRAS mutation OR KRAS wild-type amplification (copy number \geq 8). The patient's KRAS is confirmed Wild-type with no evidence of amplification. This is a key unmet inclusion criterion, making the patient ineligible for this trial. The trial is specifically designed for patients with KRAS mutations or high-level KRAS amplification, and this patient does not meet that requirement.

Disclaimer: ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06634589](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.99

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR T790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR EXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: NOT MATCH

Justification: The trial targets B-cell malignancies (B-cell Lymphoma, Relapsed/Refractory B-cell Malignancy, etc.). The patient has Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletion, which is a lung adenocarcinoma — not a B-cell malignancy. These are entirely different cancer types with no overlap.

5. Eligibility Criteria Assessment

Summary: 0 met/clear | 1 unmet | 6 uncertain

Unmet Criteria

Criterion	Type	Status
[DIAGNOSIS] Confirmed diagnosis of a R/R B-cell malignancy - Patient has NSCLC, not a B-cell malignancy	Inclusion	Unmet / Triggered

Uncertain Criteria

Criterion	Type	Status
[IMAGING] Protocol-defined measurable disease	Inclusion	Uncertain
[PERFORMANCE_STATUS] Stable ECOG Performance Status of 0 to 2	Inclusion	Uncertain
[ORGAN_FUNCTION] Adequate organ function	Inclusion	Uncertain
[ORGAN_FUNCTION] Substudies 1, 3, and 4: Adequate renal function (eGFR \geq 50 mL/min)	Inclusion	Uncertain
[PRIOR_TREATMENT] Substudy 2: BTK inhibitor-naive or previously received covalent BTK inhibitor discontinued for reasons other than clinical progression	Inclusion	Uncertain
[ORGAN_FUNCTION] Substudy 2: Adequate renal function (eGFR \geq 30 mL/min)	Inclusion	Uncertain

6. Overall Rationale

The patient has Non-Small Cell Lung Cancer (metastatic lung adenocarcinoma with EGFR exon 19 deletion), which does not match the trial's disease targets of B-cell malignancies (B-cell lymphoma, relapsed/refractory B-cell malignancy). This is a fundamental disease mismatch, making the patient ineligible for this trial regardless of other criteria.

***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*

Clinical Trials Report

produced by ClinixBoost LLC

Generated on April 28, 2026 at 03:55 PM

Trial Source Contacts

1. Overall Match Result

Patient: Anonymous Patient

Clinical Trial: [NCT06946797](#)

Trial Source: 

Result: **NO MATCH**

Confidence Score: 0.97

2. Document Source

Input Method: Clinical notes entered manually

3. Clinical Notes

70 year old male with EGFR mutated exon 19 mutation metastatic adenocarcinoma of the lung, other mutations are negative, progressed on osimertinib. He has bone and lung and liver metastasis ECOG is 0
PT has normal laboratory function, EGFR over 60ml/min, liver function normal, CBC normal
no toxicity from Osimertinib
pt is HIV negative, hpe C negative

--- Clarified Information ---

- Bilirubin results: $\leq 1.5 \times \text{ULN}$
- AST results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ALT results: $\leq 5 \times \text{ULN}$ (liver metastases)
- ANC results: $\geq 1500/\mu\text{L}$
- Platelets results: $\geq 100000/\mu\text{L}$
- EGFR results: $\geq 60 \text{ mL/min}$
- Hemoglobin results: $\geq 10 \text{ g/dL}$
- HER2 status: Negative
- Creatinine results: $\leq 1.5 \times \text{ULN}$
- BRAF status: Wild-type
- ALK status: Negative
- KRAS status: Wild-type

- Is your WBC $\geq 3000/\mu\text{L}$: Yes
- ROS1 status: Negative
- ER status: Doesn't apply
- RET status: Negative
- NTRK status: Negative
- HPV status: Doesn't apply
- NRAS status: Wild-type
- EGFR T790M status: Progressed after standard targeted therapy
- PR status: Doesn't apply
- PSA status: Doesn't apply
- Alkaline Phosphatase results: $\leq 5 \times \text{ULN}$ (liver or bone metastases)
- Mammaprint status: Doesn't apply
- Is your KRAS G12C Mutated: No
- Is your ALK Mutated: No
- Is your ROS Mutated: No
- Is your BRAF V600E Mutated: No
- Is your HR Positive: Doesn't apply
- Is your METEXON14SKIPPING Mutated: No
- Is your Egfrsensitizing Wild-type: No
- Is your BRAFV600E Wild-type: Yes
- QTC results: $\leq 450 \text{ msec}$ (men)
- Tumoractivatingfusions status: Negative
- Is your EGFR EXON20INSERTION Exon 20 insertion: No
- Is your KRASG12R G12R Mutated: No

4. Disease Target Assessment

Disease Target Result: MATCH

Justification: The patient has a confirmed diagnosis of Non-Small Cell Lung Cancer (adenocarcinoma histology, metastatic stage), which directly matches the disease targets 'Non-Small Cell Lung Cancer' and 'Carcinoma, Non-Small-Cell Lung'.

5. Eligibility Criteria Assessment

Summary: 18 met/clear | 2 unmet | 0 uncertain

Unmet Criteria

Criterion	Type	Status
[PRIOR_TREATMENT] No prior systemic anti-cancer treatment for advanced/metastatic disease - Patient has received osimertinib (an EGFR inhibitor) as primary therapy for metastatic disease and has progressed on it. This directly violates the requirement for no prior systemic anti-cancer treatment for advanced/metastatic disease.	Inclusion	Unmet / Triggered

Criterion	Type	Status
[BIOMARKER] No known driver mutations with available targeted therapy - Patient has an EGFR exon 19 deletion mutation, which is a known driver mutation sensitive to available targeted inhibitor therapy (e.g., osimertinib). This criterion explicitly excludes patients with EGFR mutations sensitive to available targeted inhibitors.	Inclusion	Unmet / Triggered

Met / Clear Criteria

Criterion	Type	Status
[DISEASE_STAGE] Stage IV or recurrent NSCLC of squamous or non-squamous histology - Patient has metastatic (stage IV) NSCLC with adenocarcinoma (non-squamous) histology.	Inclusion	Met / Clear
[PERFORMANCE_STATUS] ECOG Performance Status \leq 1 - Patient has ECOG 0.	Inclusion	Met / Clear
[CNS] No untreated CNS metastases - No CNS metastases documented.	Inclusion	Met / Clear
[CNS] No leptomeningeal metastases - Not documented in patient notes.	Inclusion	Met / Clear
[AUTOIMMUNE] No active, known or suspected autoimmune disease - No autoimmune disease documented.	Inclusion	Met / Clear
[COMORBIDITY] No prior malignancies exclusion triggered - No significant comorbidities documented.	Inclusion	Met / Clear
[MEDICATION] No systemic corticosteroids >10 mg/day or immunosuppressives within required timeframe - No such medications documented.	Inclusion	Met / Clear
[COMORBIDITY] No history of interstitial lung disease or pneumonitis requiring glucocorticoids - Not documented.	Inclusion	Met / Clear
[PRIOR_TREATMENT] No prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody treatment - Only osimertinib documented.	Inclusion	Met / Clear
[IMAGING] Measurable disease by CT/MRI per RECIST 1.1 - Procedural - completable at enrollment.	Inclusion	Met / Clear
[TIMING] Timing criteria for prior chemoradiation or adjuvant/neoadjuvant chemotherapy - Not applicable; patient had no prior chemoradiation.	Inclusion	Met / Clear
No prior anti-PD-1/PD-L1/PD-L2/CTLA-4 treatment - Only osimertinib documented.	Exclusion	Met / Clear
No untreated CNS metastases - None documented.	Exclusion	Met / Clear
No leptomeningeal metastases - None documented.	Exclusion	Met / Clear
No active autoimmune disease - None documented.	Exclusion	Met / Clear
No history of ILD/pneumonitis requiring glucocorticoids - None documented.	Exclusion	Met / Clear
No systemic corticosteroids or immunosuppressives within required timeframe - None documented.	Exclusion	Met / Clear
ALK, ROS1, BRAF V600E, KRAS G12C, RET, NTRK - all negative/wild-type per clinician confirmation.	Exclusion	Met / Clear

6. Overall Rationale

The patient has metastatic NSCLC (adenocarcinoma) which matches the disease target. However, the patient is ineligible for two key reasons: (1) The patient has already received osimertinib as primary systemic therapy for advanced/metastatic disease, violating the requirement for no prior systemic anti-cancer treatment for advanced or metastatic disease. (2) The patient has a known EGFR exon 19 deletion mutation, which is a

driver mutation sensitive to available targeted therapy, explicitly excluded by the biomarker criterion. Both of these are clear unmet inclusion criteria, resulting in a NO_MATCH determination.

***Disclaimer:** ClinixBoost LLC uses advanced generative AI trained on clinical data and trusted guidelines like ClinicalTrials.gov, NCCN and payer drug policies. It supports, but does not replace, clinical judgment. While efforts are made to ensure accuracy, the tool may not account for all patient-specific factors or the latest updates. Clinicians should review AI outputs alongside their own expertise, with final care decisions made by medical professionals.*